Table 1.
Metabolic parameters, renal function, BP, and requirements for antihypertensive treatment in study arms
Parameter and Study Moment | KD (n=104) | LPD (n=103) | P Valuec |
---|---|---|---|
Renal function | |||
eGFR (ml/min) | |||
Baseline | 18.0 (15.5 to 20.1) | 17.9 (14.3 to 19.3) | 0.68 |
End of study | 15.1 (13.2 to 17.4) | 10.8 (9.0 to 12.2) | <0.01 |
Proteinuria (g/d)a | |||
Baseline | 0.88 (0.79 to 0.96) | 0.88 (0.82 to 0.96) | 0.73 |
End of study | 0.78 (0.67 to 0.85) | 0.67 (0.57 to 0.81) | 0.06 |
BPb | |||
Mean arterial BP (mmHg) | |||
Baseline | 86 (78 to 96) | 93 (86 to 96) | 0.06 |
End of study | 90 (86 to 92) | 87 (83 to 93) | 0.42 |
Patients with optimal BP controlc (%) | |||
Baseline | 91 | 89 | 0.67 |
End of study | 85 | 84 | 0.95 |
Patients on antihypertensive drugs (%) | |||
Baseline | 86 | 89 | 0.55 |
End of study | 88 | 93 | 0.24 |
Patients receiving ACEIs and/or ARBs (%) | |||
Baseline | 71 | 71 | 0.96 |
End of study | 71 | 70 | 0.84 |
Nitrogen waste products | |||
Serum urea (mg/dl)d | |||
Baseline | 187 (164 to 225) | 213 (183 to 248) | 0.73 |
End of study | 122 (114 to 127) | 226 (191 to 252) | <0.01 |
Serum uric acid (mg/dl)e | |||
Baseline | 6.5 (6.5 to 6.6) | 6.3 (6.2 to 6.3) | 0.06 |
End of study | 6.0 (5.8 to 6.1) | 6.3 (6.1 to 6.4) | 0.01 |
Acid-base balance | |||
Serum bicarbonate (mEq/L) | |||
Baseline | 16.7 (15.8 to 17.6) | 16.8 (15.9 to 17.8) | 0.98 |
End of study | 22.9 (21.7 to 24.1) | 16.2 (15.4 to 16.9) | <0.01 |
Sodium bicarbonate supplementation | |||
Patients treated (%) | |||
Baseline | 36 | 40 | 0.53 |
End of study | 29 | 51 | <0.01 |
Prescribed dose (g/d) | |||
Baseline | 2.0 (2.0 to 2.4) | 2.0 (1.6 to 2.4) | 0.63 |
End of study | 2.2 (2.0 to 2.6) | 3.2 (2.4 to 3.6) | 0.03 |
Calcium-phosphorus metabolism | |||
Serum calcium (mg/dl) | |||
Baseline | 3.8 (3.7 to 3.9) | 3.8 (3.7 to 4.0) | 0.61 |
End of study | 4.4 (4.3 to 4.5) | 3.9 (3.7 to 3.9) | <0.01 |
Serum phosphates (mg/dl) | |||
Baseline | 5.9 (5.3 to 6.2) | 5.8 (5.2 to 6.1) | 0.68 |
End of study | 4.4 (4.3 to 4.5) | 6.2 (5.8 to 6.5) | <0.01 |
Calcium supplementation | |||
Patients treated (%) | |||
Baseline | 46 | 40 | 0.35 |
End of study | 49 | 51 | 0.72 |
Prescribed dose (g/d) | |||
Baseline | 6.1 (5.7 to 6.5) | 6.0 (5.6 to 6.5) | 0.91 |
End of study | 6.3 (6.0 to 6.6) | 6.9 (6.6 to 7.3) | <0.01 |
Vitamin D therapy (patients %) | |||
Baseline | 22 | 30 | 0.19 |
End of study | 22 | 54 | <0.01 |
Values at randomization were compared with those at the end of the study (i.e., reach of the EPP or end of the follow-up period). Data are shown as median and 95% CI. To convert eGFR in milliliters per minute to milliliters per second, multiply by 0.01667. To convert serum urea in milligrams per deciliter to millimoles per liter, multiply by 0.357. To convert serum urea in milligrams per deciliter to BUN in milligrams per deciliter, divide by 2.14. To convert serum creatinine in milligrams per deciliter to ± moles per liter, multiply by 88.4. To convert serum bicarbonate in equivalents per liter to millimoles per liter, multiply by 1. To convert serum calcium in milligrams per deciliter to millimoles per liter, multiply by 0.2495. To convert serum phosphates in milligrams per deciliter to millimoles per liter, multiply by 0.3229. To convert serum albumin in grams per deciliter to grams per liter, multiply by 10.
See also Supplementary Figure 1.
See also Supplementary Figure 2.
Arterial BP<130/75 mmHg.
See also Supplementary Figure 3.
See also Supplementary Figure 4.